




# Beat AML Master Trial

Amy Burd, PhD



# BEAT AML STUDY DESIGN


## PHASE 2, NEWLY DIAGNOSED AML



### Diagnostics Assessed:

- Cytogenetics-locally with central review (Dr. N. Heerema)
- Broad NGS genomic analysis (Foundation Medicine)
- FLT3 ITD and TKD (PCR based assay, Invivoscribe)

Treatment Assigned: Centrally (JCB, RL, BD)



- November 2016
- 16 clinical sites
- 7 Pharmaceutical Companies
- 11 Sub-studies
- Over 600 patients

# CHALLENGES

## Start Up

- Pharmaceutical commitment
- Diagnostic Assay
- Clinical Trial Culture
- Design of database, TMF, etc.

## Operations

- Data, data, data
- Monitoring
- On-going safety reporting
- Maintaining a “pipeline”
- Pharmaceutical commitment